JPRN-jRCT2080221506未知1 期
Phase I Study of TAS-102 Administered to Japanese Patients with Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Signed, written informed consent.
- •- Histologically or cytologically confirmed solid tumor.
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
排除标准
- •- Patient who has serious concomitant disease
研究者
相似试验
已完成
1 期
A phase I/II trial of TAS-102 in combination with irinotecan in Japanese patients with advanced gastric cancer refractory to standard chemotherapiesadvanced gastric cancer refractory to standard chemotherapiesJPRN-UMIN000031346St. Marianna University School of Medicine11
已完成
2 期
Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapyadvanced gastric cancerJPRN-UMIN000007421ational Cancer Center Hospital East28
进行中（未招募）
2 期
Phase II clinical study of TR-012001 in Japanese patients with Parkinson's diseaseParkinson's diseaseJPRN-jRCT2061230065Kanazashi Shuichi12
已完成
2 期
A phase II study of TAS102 for advanced/recurrent esophageal cancer resistant/intolerable to 5-FU, Platinum compounds, and Taxanenresectable, advanced or recurrent esophageal cancerJPRN-UMIN000019268Kyoto University Hospital40
已完成
2 期
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies(WJOG8916G)Metastatic RAS wild type colorectal cancer which has become refractory or there was intolerance to chemotherapies (fluoropyrimidine, irinotecan, oxaliplatin) and bevacizumab, and refractory to anti-epidermal growth factor receptor(EGFR) antibodiesJPRN-UMIN000027210West Japan Oncology Group55